FIELD: medicine, therapeutic immunology, pharmacy.
SUBSTANCE: invention proposes developed methods for preparing silent anti-CD28-antibodies. Method for preparing antibodies involves culturing the a host-cell under suitable conditions followed by isolation of expressed antibodies. Also, invention describes a pharmaceutical composition, expressing vector, antibodies and a method for treatment of organ-transplant or tissue patient rejection. Invention provides expanding assortment of agents designated for prophylaxis of transplant rejection.
EFFECT: improved preparing and treatment methods, valuable medicinal properties of antibodies.
25 cl, 3 tbl, 20 dwg, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | 2015 |
|
RU2670147C1 |
| PHARMACEUTICAL COMPOSITION FOR IMMUNE DISEASE TREATMENT | 2000 |
|
RU2203682C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| HUMANIZED ANTIBODY TO CD52 | 2012 |
|
RU2605307C2 |
| AGENTS FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASES | 2002 |
|
RU2281118C2 |
| HUMANIZED ANTIBODIES TO CTLA4 | 2012 |
|
RU2629768C2 |
| RECOMBINANT ANTIBODY WITH SPECIFICITY TO CD4, METHOD OF ITS PREPARING AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PATIENTS WITH PSORIASIS | 1992 |
|
RU2170256C2 |
| PD-1 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2722451C1 |
| HUMANIZED MONOCLONAL ANTIBODY RAISED AGAINST AILIM, CO-STIMULATING MOLECULE FOR SIGNAL TRANSFER AND ITS PHARMACEUTICAL APPLYING | 2001 |
|
RU2262511C2 |
| ILT17 ANTIBODY | 2012 |
|
RU2599450C2 |
